Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Richard J. Lin, Soo Jung Kim, Samantha Brown, Danielle M Hanley, Danielle E Engstler, Ioannis Politikos, Boglarka Gyurkocza, Roni Tamari, Esperanza B. Papadopoulos, Amethyst Saldia, Yetunde Aremu, Aaron D. Goldberg, Mark Blaine Geyer, Eytan M. Stein, Miguel Angel Perales, Beatriz Korc-Grodzicki, Sean M. Devlin, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 686.

https://doi.org/10.1182/blood-2024-207934

Published: 2024

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Journal Articles

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Melinda Cook, Grashma Vadakkel, Stephanie Chinapen, Miguel-Angel Perales, Roni Tamari, Esperanza B. Papadopoulos, Doris M. Ponce, Brian C. Shaffer, Andrew Lin

Blood (2024) 144 (Supplement 1): 7356.

https://doi.org/10.1182/blood-2024-200361

Published: 2024

Journal Articles

Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells

Benjamin Kroger, Roni Tamari, Carmelo Gurnari, Julio Alvarenga Thiebaud, Alejandro Marinos Velarde, Yazan F Madanat, Robert H. Collins, Clayton Jackson, Vivian Irizarry Gatell, Valeria Visconte, Jaroslaw Maciejewski, David Sallman, Stephen Chung

Blood (2024) 144 (Supplement 1): 777.

https://doi.org/10.1182/blood-2024-212380

Published: 2024

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela S. Hobbs, Haesook T. Kim, Suzanne O'Connor, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Areej El-Jawahri, Steven McAfee, Jessica Hem, Patricia Lozano, Jonas S. Jutzi, Ann Mullally, Yi-Bin Chen, Zachariah Defilipp

Blood (2023) 142 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2023-178645

Published: 2023

Journal Articles

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Ioannis Politikos, Sean M. Devlin, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2023-190528

Published: 2023

Journal Articles

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Jelena Ostojić, Rizi Ai, Tara Maier, Mario Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew Harris, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 777.

https://doi.org/10.1182/blood-2023-182198

Published: 2023

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Ioannis Politikos, Warren B Fingrut, Samantha Brown, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Miguel-Angel Perales, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2023-190836

Published: 2023

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

Eric Davis, Elise Feuer, Candice Rapoport, Stephanie Lobaugh, Sean M. Devlin, Anne Archer, Stephanie Chinapen, Jacob Federman, Amanda Kelly, Elizabeth Klein, Melissa Nhaissi, Deborah Wells, Juliet N Barker, Esperanza B. Papadopoulos, Andromachi Scaradavou, Jaap Jan Boelens, Miguel-Angel Perales, Elena Maryamchik, Roni Tamari

Blood (2023) 142 (Supplement 1): 113.

https://doi.org/10.1182/blood-2023-190940

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Shlomo Elias, Moneeza Walji, Samantha Brown, Sean M. Devlin, Esperanza B. Papadopoulos, Ann A Jakubowski, Doris M Ponce, James W. Young, Sergio A Giralt, Miguel-Angel Perales, Brian C. Shaffer, Parastoo B. Dahi, Richard J. Lin, Christina Cho, Roni Tamari, Melody Smith, Boglarka Gyurkocza

Blood (2022) 140 (Supplement 1): 10627–10628.

https://doi.org/10.1182/blood-2022-170088

Published: 2022

Journal Articles

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Blood (2022) 140 (Supplement 1): 4759–4761.

https://doi.org/10.1182/blood-2022-159303

Published: 2022

Journal Articles

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

Maria Stefania Infante, Susan DeWolf, Roni Tamari, Parastoo B. Dahi, Yeon Joo Lee, Ioannis Politikos, Juliet N. Barker, N. Esther Babady, Lakshmi Ramanathan, Susan Seo, Sergio A. Giralt, Mini Kamboj, Miguel-Angel Perales, Gunjan L. Shah

Blood (2022) 140 (Supplement 1): 4792–4794.

https://doi.org/10.1182/blood-2022-166393

Published: 2022

Journal Articles

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Hillard M Lazarus, Joseph P. McGuirk, Tsila Zuckerman, Leland Metheny, Luis Pineiro, Mark R. Litzow, Scott D. Rowley, Batia Avni, Roni Tamari, Michal Sheleg, Daniel Rothenstein, Nitsan Halevy, Jacob M. Rowe

Blood (2022) 140 (Supplement 1): 10447–10448.

https://doi.org/10.1182/blood-2022-169266

Published: 2022

Journal Articles

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Benjamin Kroger, Yi Huang, Prapti Patel, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Jr., Farrukh T. Awan, Praveen Ramakrishnan, Kunal Verma, Russell Vittrup, Robert H. Collins, Madhuri Vusirikala, Yazan F. Madanat, Roni Tamari, Stephen S. Chung

Blood (2022) 140 (Supplement 1): 9833–9835.

https://doi.org/10.1182/blood-2022-171179

Published: 2022

Journal Articles

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Blood (2022) 140 (Supplement 1): 2137–2139.

https://doi.org/10.1182/blood-2022-157193

Published: 2022

Journal Articles

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela Hobbs, Haesook T. Kim, AJ S. Bottoms, Michael T. Byrne, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Zachariah Defilipp, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen

Blood (2021) 138 (Supplement 1): 169.

https://doi.org/10.1182/blood-2021-146330

Published: 2021

NARROW

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only